<?xml version="1.0" encoding="UTF-8"?>
<p>BGR-34 is an ayurvedic polyherbal antidiabetic formulation claimed to be jointly developed by the Council of Scientific &amp; Industrial Research, India (CSIR), National Botanical Research Institute (NBRI), and Central Institute for Medicinal and Aromatic Plant (CIMAP). The formulation contains varieties of herbal ingredients like the stem of Daruharidar (
 <italic>Berberis aristata</italic>) and Giloy (
 <italic>Tinospora cordifolia</italic>), the heartwood of Vijaysar (
 <italic>Pterocarpus marsupium</italic>), Gudmar leaves (
 <italic>Gymnema sylvestre</italic>), Manjeet root (
 <italic>Rubia cordifolia</italic>), and Methika seeds (
 <italic>Trigonella foenumgraecum</italic>). AIMIL Pharmaceuticals (India) Ltd. owns the license for the manufacturing and marketing of BGR-34 around the globe. Further, the clinical studies on BGR-34 confirms that it postulates several mechanisms that are clinically relevant and statistically significant in the reduction of the three key measures of glucose control such as fasting plasma glucose (FPG), improved postprandial glucose (PPBG), and hemoglobin A1c (HbA1c). The trial is registered to the clinical trial registry of India (CTRI registration number: CTRI/2016/11/007476).
 <sup>
  <xref ref-type="bibr" rid="ref9">9</xref>
 </sup>
</p>
